Cannabinoids and neuroprotection in CNS inflammatory disease

Journal of the Neurological Sciences

Volumn 233, Issue 1-2, 2005, Pages 21-25

  Jackson, Samuel J ^a   Diemel, Lara T ^a   Pryce, Gareth ^a   Baker, David ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cannabinoid; CB1; Experimental allergic encephalomyelitis; Multiple sclerosis; Review

Indexed keywords

ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; DRONABINOL; ENDOCANNABINOID; NITRIC OXIDE; PEROXYNITRITE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANTIOXIDANT ACTIVITY; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; ENCEPHALITIS; EXCITOTOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE ACTIVATION; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPROTECTION; NEUROTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; CANNABINOIDS; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS;

EID: 20444383156     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2005.03.002     Document Type: Conference Paper

References (54)

1. A. Compston, and A. Coles Multiple sclerosis Lancet 359 2002 1221 1231
2. M.H. Barnett, and J.W. Prineas Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion Ann Neurol 55 2004 458 468
3. M. Schwartz, and J. Kipnis Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity: a paradigm shift Neuroscientist 8 2002 405 413
4. C. Bjartmar, and B.D. Trapp Axonal degeneration and progressive neurologic disability in multiple sclerosis Neurotox Res 5 2003 157 164
5. C. Bjartmar, J.R. Wujek, and B.D. Trapp Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease J Neurol Sci 206 2003 165 171
6. K.J. Smith, R. Kapoor, S.M. Hall, and M. Davies Electrically active axons degenerate when exposed to nitric oxide Ann Neurol 49 2001 470 476
7. A.J. Coles, M.G. Wing, P. Molyneux, A. Paolillo, C.M. Davie, and G. Hale Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis Ann Neurol 46 1999 296 304
8. M. Inglese, G.L. Mancardi, E. Pagani, M.A. Rocca, A. Murialdo, and R. Saccardi Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation J Neurol Neurosurg Psychiatry 75 2004 643 644
9. G.N. Chaturvedi, S.K. Tiwari, and N.P. Rai Medicinal use of opium and cannabis in medieval India Indian J Hist Sci 16 1981 31 35
10. R.G. Pertwee Cannabinoids and multiple sclerosis Pharmacol Ther 95 2002 165 174
11. A.C. Howlett The cannabinoid receptors Prostaglandins Other Lipid Mediat 68-69 2002 619 631
12. R.I. Wilson, and R.A. Nicoll Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses Nature 410 2001 588 592
13. A.C. Kreitzer, and W.G. Regehr Retrograde signaling by endocannabinoids Curr Opin Neurobiol 12 2002 324 330
14. D. Baker, G. Pryce, J.L. Croxford, P. Brown, R.G. Pertwee, and J.W. Huffman Cannabinoids control spasticity and tremor in a multiple sclerosis model Nature 404 2000 84 87
15. D. Baker, G. Pryce, J.L. Croxford, P. Brown, R.G. Pertwee, and A. Makriyannis Endocannabinoids control spasticity in a multiple sclerosis model FASEB J 15 2001 300 302
16. D.T. Wade, P. Robson, H. House, P. Makela, and J. Aram A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms Clin Rehabil 17 2003 21 29
17. J. Zajicek, P. Fox, H. Sanders, D. Wright, J. Vickery, and A. Nunn Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial Lancet 362 2003 1517 1526
18. J. Killestein, E.L. Hoogervorst, M. Reif, N.F. Kalkers, A.C. Van Loenen, and P.G. Staats Safety, tolerability, and efficacy of orally administered cannabinoids in MS Neurology 58 2002 1404 1407
19. A. Zimmer, A.M. Zimmer, A.G. Hohmann, M. Herkenham, and T.I. Bonner Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice [see comments] Proc Natl Acad Sci U S A 96 1999 5780 5785
20. C. Ledent, O. Valverde, G. Cossu, F. Petitet, J.F. Aubert, and F. Beslot Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 283 1999 401 404
21. D. Baker, G. Pryce, G. Giovannoni, and A.J. Thompson The therapeutic potential of cannabis Lancet Neurol 2 2003 291 298
22. C.C. Chao, S. Hu, W.S. Sheng, D. Bu, M.I. Bukrinsky, and P.K. Peterson Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism Glia 16 1996 276 284
23. T.P. Misko, J.L. Trotter, and A.H. Cross Mediation of inflammation by encephalitogenic cells: interferon gamma induction of nitric oxide synthase and cyclooxygenase 2 J Neuroimmunol 61 1995 195 204
24. L.J. van der Laan, S.R. Ruuls, K.S. Weber, I.J. Lodder, E.A. Dopp, and C.D. Dijkstra Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide J Neuroimmunol 70 1996 145 152
25. S.A. Lipton, Y.B. Choi, Z.H. Pan, S.Z. Lei, H.S. Chen, and N.J. Sucher A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds Nature 364 1993 626 632
26. R. Kapoor, M. Davies, P.A. Blaker, S.M. Hall, and K.J. Smith Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration Ann Neurol 53 2003 174 180
27. M. Arundine, and M. Tymianski Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity Cell Calcium 34 2003 325 337
28. M. Leist, C. Volbracht, S. Kuhnle, E. Fava, E. Ferrando-May, and P. Nicotera Caspase-mediated apoptosis in neuronal excitotoxicity triggered by nitric oxide Mol Med 3 1997 750 764
29. T. Smith, A. Groom, B. Zhu, and L. Turski Autoimmune encephalomyelitis ameliorated by AMPA antagonists Nat Med 6 2000 62 66
30. A.J. Groom, T. Smith, and L. Turski Multiple sclerosis and glutamate Ann N Y Acad Sci 993 2003 229 275
31. M. Shen, and S.A. Thayer Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity Mol Pharmacol 54 1998 459 462
32. T. Nagayama, A.D. Sinor, R.P. Simon, J. Chen, S.H. Graham, and K. Jin Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures J Neurosci 19 1999 2987 2995
33. A.D. Sinor, S.M. Irvin, and D.A. Greenberg Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats Neurosci Lett 278 2000 157 160
34. M.E. Abood, G. Rizvi, N. Sallapudi, and S.D. McAllister Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity Neurosci Lett 309 2001 197 201
35. G. Pryce, Z. Ahmed, D.J. Hankey, S.J. Jackson, J.L. Croxford, and J.M. Pocock Cannabinoids inhibit neurodegeneration in models of multiple sclerosis Brain 126 2003 2191 2202
36. D. Panikashvili, C. Simeonidou, S. Ben Shabat, L. Hanus, A. Breuer, and R. Mechoulam An endogenous cannabinoid (2-AG) is neuroprotective after brain injury Nature 413 2001 527 531
37. A.J. Hampson, M. Grimaldi, J. Axelrod, and D. Wink Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants Proc Natl Acad Sci U S A 95 1998 8268 8273
38. G. Marsicano, B. Moosmann, H. Hermann, B. Lutz, and C. Behl Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1 J Neurochem 80 2002 448 456
39. A.B. El Remessy, I.E. Khalil, S. Matragoon, G. Abou-Mohamed, N.J. Tsai, and P. Roon Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-d-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite Am J Pathol 163 2003 1997 2008
40. M. van der Stelt, W.B. Veldhuis, P.R. Bar, G.A. Veldink, J.F. Vliegenthart, and K. Nicolay Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity J Neurosci 21 2001 6475 6479
41. M. van der Stelt, W.B. Veldhuis, G.W. van Haaften, F. Fezza, T. Bisogno, and P.R. Bar Exogenous anandamide protects rat brain against acute neuronal injury in vivo J Neurosci 21 2001 8765 8771
42. H.H. Hansen, I. Azcoitia, S. Pons, J. Romero, L.M. Garcia-Segura, and J.A. Ramos Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity J Neurochem 82 2002 154 158
43. S.J. Jackson, D. Baker, M.L. Cuzner, and L.T. Diemel Cannabinoid-mediated neuroprotection following interferon-gamma treatment in a 3D mouse brain aggregate cell culture Eur J Neurosci 20 2004 2267 2275
44. W.D. Lyman, J.R. Sonett, C.F. Brosnan, R. Elkin, and M.B. Bornstein Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis J Neuroimmunol 23 1989 73 81
45. I. Wirguin, R. Mechoulam, A. Breuer, E. Schezen, J. Weidenfeld, and T. Brenner Suppression of experimental autoimmune encephalomyelitis by cannabinoids Immunopharmacology 28 1994 209 214
46. J.L. Croxford, and S.D. Miller Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R + WIN55,212 J Clin Invest 111 2003 1231 1240
47. F. Molina-Holgado, A. Lledo, and C. Guaza Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes Neuroreport 8 1997 1929 1933
48. D.L. Gruol, D.D. Sweeney, S.M. Conroy, C. Trotter, J.G. Netzeband, and Z. Qiu Cannabinoids alter neurotoxicity produced by interleukin-6 in central nervous system neurons Adv Exp Med Biol 437 1998 231 240
49. F. Facchinetti, E. Del Giudice, S. Furegato, M. Passarotto, and A. Leon Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide Glia 41 2003 161 168
50. R.A. Puffenbarger, A.C. Boothe, and G.A. Cabral Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells Glia 29 2000 58 69
51. N. Germain, E. Boichot, C. Advenier, E.V. Berdyshev, and V. Lagente Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells Int Immunopharmacol 2 2002 537 543
52. A. Arevalo-Martin, J.M. Vela, E. Molina-Holgado, J. Borrell, and C. Guaza Therapeutic action of cannabinoids in a murine model of multiple sclerosis J Neurosci 23 2003 2511 2516
53. R. Gallily, A. Yamin, Y. Waksmann, H. Ovadia, J. Weidenfeld, and A. Bar-Joseph Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid J Pharmacol Exp Ther 283 1997 918 924
54. E. De Lago, A. Ligresti, G. Ortar, E. Morera, A. Cabranes, and G. Pryce In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake Eur J Pharmacol 484 2004 249 257